Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

02 avr. 2026 11h55 HE | Source: Research and Markets

Global Interventional Oncology Industry Set to Grow by $1.18 Billion During 2026-2030 - AI-Assisted Imaging and Minimally Invasive Procedures Drive Interventional Oncology Expansion

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Interventional Oncology Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market...
02 avr. 2026 11h51 HE | Source: Research and Markets

Global Tumor Models Market Set to Soar from $2.37B in 2026 to $3.57B by 2030 - 3D Spheroids and Organ-on-a-Chip Propel Tumor Model Advancements

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Models Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor models market has been experiencing rapid growth,...
02 avr. 2026 11h31 HE | Source: Research and Markets

Tumor Microenvironment Market to Reach Over $2.7 Billion by 2030 - Rising Demand for Personalized Oncology Therapies and Next-Gen Immunotherapies Driving the Industry

Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Tumor Microenvironment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The tumor microenvironment (TME) market has...
31 mars 2026 09h15 HE | Source: Alpha Tau Medical Ltd.

Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026

JERUSALEM, March 31, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) (“Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced...
30 mars 2026 05h51 HE | Source: Research and Markets

Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Pancreatic Adenocarcinoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The pancreatic adenocarcinoma...
30 mars 2026 05h37 HE | Source: Research and Markets

Uveal Neoplasms Markets, Companies, and Investment Opportunities Analysis 2026-2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Uveal Neoplasms Market Report 2026" has been added to ResearchAndMarkets.com's offering. The global uveal neoplasms market has demonstrated...
27 mars 2026 11h12 HE | Source: Research and Markets

Competitive Insights and Expert Consultation on the Growing Oncology Nutrition Market, 2026-2030: A $3.27 Billion Opportunity

Dublin, March 27, 2026 (GLOBE NEWSWIRE) -- The "Oncology Nutrition Market Report 2026" has been added to ResearchAndMarkets.com's offering. The oncology nutrition market has shown robust...
18 mars 2026 17h31 HE | Source: Marker Therapeutics

Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results

Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50% complete responses Research published in...
18 mars 2026 08h36 HE | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors

OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent...
12 mars 2026 08h45 HE | Source: Propanc Biopharma, Inc.

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

Page suivante